VRDN Latest Headlines

Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), MDxHealth (MDXH) and RxSight (RXST)

at www.tipranks.com (Tue, 23-Dec 7:30 AM)

Viridian Therapeutics: De-Risked Veligrotug Program and Compelling Phase III Data Support Undervalued Buy Rating

at www.tipranks.com (Tue, 23-Dec 5:45 AM)

Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Sanofi (OtherSNYNF)

at www.tipranks.com (Tue, 23-Dec 5:40 AM)

Viridian’s Veligrotug Advances with FDA Priority Review—Pivotal Data Shows Robust, Rapid Results for Thyroid Eye Disease

Market Chameleon (Mon, 22-Dec 11:17 AM)

Analysts Are Bullish on These Healthcare Stocks: Simulations Plus (SLP), Viridian Therapeutics (VRDN)

at www.tipranks.com (Mon, 22-Dec 12:30 PM)

Viridian: Priority Review for Veligrotug and Catalyst-Rich 2026 Outlook Drive Price Target Raise and Buy Rating

at www.tipranks.com (Mon, 22-Dec 12:16 PM)

Viridian Therapeutics (VRDN) Receives a Buy from Wedbush

at www.tipranks.com (Mon, 22-Dec 8:35 AM)

Analysts Have Conflicting Sentiments on These Healthcare Companies: Viridian Therapeutics (VRDN), Fortrea Holdings Inc. (FTRE) and Cytokinetics (CYTK)

at www.tipranks.com (Mon, 22-Dec 8:10 AM)

Viridian Therapeutics Secures Nearly $900 Million, Eyes Profitability and Mid-2026 Product Launch

Market Chameleon (Thu, 6-Nov 10:37 AM)

Viridian Therapeutics Prices $251 Million Public Offering to Fuel Advancements in Rare Disease Therapies

Market Chameleon (Wed, 22-Oct 9:36 AM)